title: Monitoring of ovarian activity by measurement of urinary excretion rates of estrone glucuronide and pregnanediol glucuronide using the Ovarian Monitor, Part II: reliability of home testing.
abstract: BACKGROUND
  The UNDP/WHO/World Bank/Special Programme of Research, Development and Research Training in Human Reproduction (Geneva) set up a study to determine whether it is feasible for women to monitor their ovarian activity reliably by home testing. Daily self-monitoring of urinary hormone metabolites for menstrual cycle assessment was evaluated by comparison of results obtained with the Home Ovarian Monitor by untrained users both at home and in study centres.
  
  
  METHODS
  Women collected daily data for urinary estrone glucuronide (E1G) and pregnanediol glucuronide (PdG) for two cycles, then the procedure was repeated in the women's local centre (in Chile, Australia or New Zealand) giving a total of 113 duplicate cycles. The tests were performed without the benefit of replicates or quality controls. The home and centre cycles were normalized and compared to identify assay errors, and the resulting home and centre menstrual cycle profiles were averaged.
  
  
  RESULTS
  Reliable mean cycle profiles were obtained with the home and centre excretion rates agreeing to within 36 ± 21 nmol/24 h for E1G and 0.77 ± 0.28 µmol/24 h for baseline PdG values (1-5 µmol/24 h). The cycles had a mean length of 28.1 ± 3.1 days (n = 112; 5th and 95th percentiles: 24 and 35 days, respectively), a mean follicular phase of 14.8 ± 3.1 days (n = 107; 5th and 95th percentiles: 11 and 21 days) and a mean luteal phase length of 13.3 ± 1.5 days (n = 106; 5th and 95th percentiles: 11 and 17 days), calculated from the day of the LH peak.
  
  
  CONCLUSIONS
  The study confirmed that the Ovarian Monitor pre-coated assay tubes worked well even in the hands of lay users, without standard curves, quality controls or replicates. Point-of-care monitoring to give reliable fertility data is feasible.
authors: Institute of Fundamental Sciences, Massey University, Palmerston North, New Zealand. l.f.blackwell@massey.ac.nz
authors: Leonard F
authors: LF
authors: Blackwell
authors: Pilar
authors: P
authors: Vigil
authors: Barbara
authors: B
authors: Gross
authors: Catherine
authors: C
authors: d'Arcangues
authors: Delwyn G
authors: DG
authors: Cooke
authors: James B
authors: JB
authors: Brown
mesh_terms: D000328:Adult; D001315:Australia; D002677:Chile; D004970:Estrone / Q000031:analogs & derivatives* / Q000652:urine; D005240:Feasibility Studies; D005260:Female; D020719:Glucuronides / Q000652:urine*; D006801:Humans; D008422:Materials Testing; D008597:Menstrual Cycle; D009520:New Zealand; D010053:Ovary / Q000502:physiology*; D010060:Ovulation / Q000652:urine*; D010061:Ovulation Detection / Q000295:instrumentation*; D019095:Point-of-Care Systems; D011276:Pregnanediol / Q000031:analogs & derivatives* / Q000652:urine; D015203:Reproducibility of Results; D012648:Self Care
chemical_list: D020719:Glucuronides; D004970:Estrone; D011276:Pregnanediol